Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.59 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16266193 | 0.82 | HRH4 (0.66) | HRH4SSTR2KCNH2CARM1ESR1 | |
| SCHEMBL3950574 | 0.82 | HRH4 (0.46) | HRH4SSTR2KCNH2 | |
| SCHEMBL17808691 | 0.77 | HRH4 (0.80) | HRH4SSTR2KCNH2CARM1 | |
| Toreforant SCHEMBL1535698 | 0.74 | HRH4 (1.00) | HRH4SSTR2KCNH2CARM1IGF1R | |
| SCHEMBL3259837 | 0.74 | HRH4 (0.70) | HRH4SSTR2KCNH2CARM1ESR1 | |
| SCHEMBL2906825 | 0.73 | HRH4 (0.69) | HRH4SSTR2KCNH2CARM1ESR1 | |
| SCHEMBL4543952 | 0.73 | HRH4 (0.57) | HRH4 | |
| SCHEMBL3897392 | 0.73 | HRH4 (0.49) | HRH4SSTR2KCNH2CARM1 | |
| SCHEMBL2906823 | 0.73 | HRH4 (0.75) | HRH4SSTR2KCNH2CARM1IGF1R | |
| SCHEMBL3950565 | 0.73 | HRH4 (0.54) | HRH4SSTR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371311-B2 | Benzoimidazol-2-yl pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-21 | — | — | US | disclosed |
| EP-2865678-A2 | Crystalline hemi-tartrate form of a benzoimidazol-2-yl pyrimidine derivative | Janssen Pharmaceutica NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140357865-A1 | Process for the Preparation of Benzoimidazol-2-yl Pyrimidine Derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357865-A1 | Process for the Preparation of Benzoimidazol-2-yl Pyrimidine Derivatives | HRH4, HRH2, HRH3 | HRH4 1/4885SSTR2 788/4885KCNH2 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.